Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Infratil Climbs on the ASX as Its Data Centre Expansion Faces a Delivery Test
Source: Kapitales Research
Highlights
CDC helped lift Infratil’s share of operating earnings by 28%.
An incentive fee provision contributed to a NZ$247.8 million loss attributable to shareholders.
Infratil raised its FY27 earnings forecast and increased its interim dividend.
Infratil Limited (ASX: IFT) shares gained 2.5% to AU$11.050 on 18 November 2026 after the company raised its full-year earnings forecast. Proportionate operational EBITDAF, which measures Infratil’s share of operating earnings across its portfolio, rose to NZ$711 million from NZ$555 million for the six months ended 30 September 2026.
Data centre contracts underpin growth
CDC signed agreements covering 625 megawatts during the half, taking its contracted capacity to 1.1 gigawatts. Its EBITDAF climbed 84% to AU$339 million. The business expects annualised EBITDAF of AU$2.2 billion once all contracted capacity is operating.
One New Zealand and Longroad Energy each grew earnings by 10%, reaching NZ$325 million and US$91 million, respectively. Wellington Airport held at NZ$66 million, while RHCNZ was broadly steady at NZ$61 million. Qscan’s earnings fell AU$4 million to AU$39 million.
A bigger portfolio and a shareholder loss
Infratil’s CDC stake reached NZ$11.35 billion, up from NZ$8.93 billion. The revaluation led to a NZ$256 million incentive fee provision, with the final amount subject to year-end valuations. Infratil posted a NZ$247.8 million loss attributable to shareholders, compared to a restated NZ$572.8 million profit.
Portfolio asset value rose 8% to NZ$22.3 billion, while proportionate capital expenditure jumped 98% to NZ$2.1 billion. Available liquidity was about NZ$1.4 billion. Independent valuations put Infratil’s Longroad, Galileo and RHCNZ stakes at NZ$2,350.4 million, NZ$266.4 million and NZ$636.6 million, respectively. Its Anytime Radiology stake received an initial valuation of NZ$121.7 million.
Interim dividend
Infratil lifted its partially imputed interim dividend from NZ$0.0725 to NZ$0.074 per share. Shares trade ex-dividend on 1 December, ahead of payment on 21 December 2026.
Outlook
Infratil raised FY27 proportionate operational EBITDAF guidance to NZ$1.37 billion–NZ$1.44 billion from NZ$1.32 billion–NZ$1.42 billion. CDC’s forecast rose to AU$730 million–AU$770 million, while Qscan’s fell to AU$75 million–AU$85 million as its sale process continued.
With 810 megawatts of CDC capacity under construction and FY27 proportionate capital spending forecast at NZ$4.15 billion–NZ$4.45 billion, the next test for shareholders is whether sites open on schedule. Those opening dates will determine when CDC can start earning revenue from the capacity customers have already booked.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Infratil Climbs on the ASX as Its Data Centre Expansion Faces a Delivery Test
Highlights
Infratil Limited (ASX: IFT) shares gained 2.5% to AU$11.050 on 18 November 2026 after the company raised its full-year earnings forecast. Proportionate operational EBITDAF, which measures Infratil’s share of operating earnings across its portfolio, rose to NZ$711 million from NZ$555 million for the six months ended 30 September 2026.
Data centre contracts underpin growth
CDC signed agreements covering 625 megawatts during the half, taking its contracted capacity to 1.1 gigawatts. Its EBITDAF climbed 84% to AU$339 million. The business expects annualised EBITDAF of AU$2.2 billion once all contracted capacity is operating.
One New Zealand and Longroad Energy each grew earnings by 10%, reaching NZ$325 million and US$91 million, respectively. Wellington Airport held at NZ$66 million, while RHCNZ was broadly steady at NZ$61 million. Qscan’s earnings fell AU$4 million to AU$39 million.
A bigger portfolio and a shareholder loss
Infratil’s CDC stake reached NZ$11.35 billion, up from NZ$8.93 billion. The revaluation led to a NZ$256 million incentive fee provision, with the final amount subject to year-end valuations. Infratil posted a NZ$247.8 million loss attributable to shareholders, compared to a restated NZ$572.8 million profit.
Portfolio asset value rose 8% to NZ$22.3 billion, while proportionate capital expenditure jumped 98% to NZ$2.1 billion. Available liquidity was about NZ$1.4 billion. Independent valuations put Infratil’s Longroad, Galileo and RHCNZ stakes at NZ$2,350.4 million, NZ$266.4 million and NZ$636.6 million, respectively. Its Anytime Radiology stake received an initial valuation of NZ$121.7 million.
Interim dividend
Infratil lifted its partially imputed interim dividend from NZ$0.0725 to NZ$0.074 per share. Shares trade ex-dividend on 1 December, ahead of payment on 21 December 2026.
Outlook
Infratil raised FY27 proportionate operational EBITDAF guidance to NZ$1.37 billion–NZ$1.44 billion from NZ$1.32 billion–NZ$1.42 billion. CDC’s forecast rose to AU$730 million–AU$770 million, while Qscan’s fell to AU$75 million–AU$85 million as its sale process continued.
With 810 megawatts of CDC capacity under construction and FY27 proportionate capital spending forecast at NZ$4.15 billion–NZ$4.45 billion, the next test for shareholders is whether sites open on schedule. Those opening dates will determine when CDC can start earning revenue from the capacity customers have already booked.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au